Informations générales (source: ClinicalTrials.gov)
Reward and Punishment Sensitivity in Bipolar Disorders (Recodec-BP)
Observational
University Hospital, Grenoble (Voir sur ClinicalTrials)
février 2020
février 2022
29 juin 2024
Bipolar disorder (BD) represents a chronic mood disorder and one of the leading causes of
disability worldwide. Complexity of its clinical presentations leads to delayed diagnosis
and difficult management in routine clinical settings. Whereas distinguishing BD-I and
BD-II main subtypes has a significant relevance for treatment strategy and for outcome,
there are currently no clinical determinants of the BD subtype which could be used as
early diagnostic predictors.
- While neurobiological specificity of each BD subtype is still controversial,
available evidence suggest different dopaminergic abnormalities in each subtype.
Dopaminergic function is involved in decision making and reward processing which may
represent useful BD subtype markers.
- This study aims at assessing decision making during appetitive and punitive
reinforcement learning in patients with BD I and BD II subtypes compared to healthy
controls
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Chu Grenoble Alpes - 38043 - Grenoble Cedex 9 - France | Polosan Mircea | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- bipolar disorder (BD) type I or II, according to DSM (Diagnostic and Statistical
Manual)-5 criteria
- Montgomery and Asberg Depression Rating Scale (MADRS) score < 15
- Young Mania Rating Scale (YMRS) score < 12
- bipolar disorder (BD) type I or II, according to DSM (Diagnostic and Statistical
Manual)-5 criteria
- Montgomery and Asberg Depression Rating Scale (MADRS) score < 15
- Young Mania Rating Scale (YMRS) score < 12
- other main diagnosis than bipolar disorder
- other medical condition leading to cognitive deterioration